Reuters logo
BRIEF-Theratechnologies reports FDA's decision to extend ibalizumab review period to April 3, 2018​
November 14, 2017 / 12:40 PM / a month ago

BRIEF-Theratechnologies reports FDA's decision to extend ibalizumab review period to April 3, 2018​

Nov 14 (Reuters) - Theratechnologies Inc:

* Theratechnologies Inc says ‍announces decision by FDA to extend ibalizumab review period to April 3, 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below